CROs and biotech companies: Fine-tuning the partnership

McKinsey

Emerging biotechnology companies are less satisfied than large pharmaceutical companies with their contract research organizations (CROs). Insights on Life Sciences Biotechnology

What are the biotech investment themes that will shape the industry?

McKinsey

Insights on Life Sciences BiotechnologyFrom 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Building pharma pipelines using a socioeconomic lens

McKinsey

Insights on Life Sciences Biotechnology InnovationHarnessing advances in science and technology can deliver transformative therapies faster while reducing the socioeconomic burden of disease.

Innovation sourcing in biopharma: Four practices to maximize success

McKinsey

Insights on Life Sciences Pharmaceuticals Biotechnology Artificial IntelligenceBiopharma companies’ pipelines are full of assets they source externally to access innovation. Four practices will help ensure their investments flourish at a time of fierce competition.

How biotechs can rethink their strategies after the market downturn

McKinsey

Insights on Life Sciences Health Care BiotechnologyBiotech stocks have taken a hit, but the sector will probably rebound. Companies can navigate the downturn by scrutinizing cash management and financing and rethinking paths to long-term value creation.

Building a global biotech: Taking a first-time launch into international markets

McKinsey

Insights on Life Sciences Biotechnology Globalization StrategyEstablishing an international presence with a first launch is a challenge, but learning from others’ experiences can help biotechs avoid missteps and maximize their chances of success.

Gene-therapy innovation: Unlocking the promise of viral vectors

McKinsey

Insights on Pharmaceuticals & Medical Products Pharmaceuticals BiotechnologyViral-vector gene therapies show great promise, but the full extent of their clinical impact in the long term is not yet certain. Success depends on innovative solutions that remain under development.

Forward Thinking on the Bio Revolution with Jason Kelly and Dr. Michelle McMurry-Heath

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyThe leaders of Gingko Bioworks and the BIO organization discuss the future of biological technologies, from developing vaccines faster to changing how we produce food.

An inflection point for biosimilars

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology PharmaceuticalsWith rising US adoption, biosimilars are gathering even more momentum. Successful companies will innovate their commercial models, rethink their portfolio management, and accelerate their R&D.

What’s ahead for biotech: Another wave or low tide?

McKinsey

Insights on Pharmaceuticals & Medical Products Venture capital BiotechnologyEven in tough times, investor expectations and deal making in biotech are surging. Can the sector maintain its strong growth?

Precision medicine in practice: Strategies for rare cancers

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology Pharmaceuticals Oncology/CancerThe small number of people with rare diseases raises challenges for the development and launch of all therapies for such conditions, but rare cancers face extra barriers to widespread treatment.

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Pharmaceuticals and biotechnology, IVD, advanced medical technologies, medical imaging and informatics, and digital health expected to hit over $2.6

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

Healthcare News Press Releases biopharma biopharmaceutical biotechnology biotherapeutics COVID-19 vaccine logistics DNA drug mrna pharma Pharmaceutical research RNA therapeutics vaccine

Infographic: Biotech hot spots in a fragmented European landscape

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyWe mapped out 1,382 biotechs based in Europe and some interesting themes emerged.

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Pharmaceuticals and biotechnology, IVD, advanced medical technologies, medical imaging and informatics, and digital health expected to hit over $2.6

Infographic: Building the European biotech sector with world-class science and innovation

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope is a powerhouse in scientific publishing with roughly twice the output of the United States and three times that of China.

Infographic: Biotech in Europe: Driving the next act

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyHow can biotechs and investors succeed in the future? To scale up innovation, industry stakeholders need to focus on several key areas.

Infographic: Capital landscape for European biotechs is maturing, but it continues to trail the United States

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope’s biotech sector has made meaningful progress in attracting capital. However, raising more capital will be essential to the continued growth of this sector.

Infographic: Biotech in Europe: Driving the next act

McKinsey

Insights on Life Sciences BiotechnologyHow can biotechs and investors succeed in the future? To scale up innovation, industry stakeholders need to focus on several key areas.

Infographic: The McKinsey Biotech Innovation Index

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope may be catching up with the United States in biotech innovation and funding. Its overall score on the Biotech Innovation Index improved by 20 percent in 2015–17 and 2018–20.

2021 Preview: A 360-Degree Global Market View

LaVoie Health Science Blog

The “ 2021 Preview: A 360 Degree Global Market View, ” virtual webinar was designed to discuss global market trends on public and private United States, Europe, and China markets, JPM virtual week in January 2021, and more.

How DSM Merged with Firmenich: When Capabilities Complement each other

Frost & Sullivan

DSM has a strong portfolio of bio-based ingredients that will be complemented by Firmenich’s long-standing experience in natural and biotechnology-derived ingredients. In May 2022, DSM and Firmenich announced their plans to merge together.

DSM Merger with Firmenich – A Fusion of Complementary Capabilities

Frost & Sullivan

DSM has a strong portfolio of bio-based ingredients that will be complemented by Firmenich’s long-standing experience in natural and biotechnology-derived ingredients. In May 2022, DSM and Firmenich announced their plans to merge together.

LaVoieHealthScience Builds on 2020 Momentum with an Updated Team Roster to Meet Client Growth in 2021

LaVoie Health Science Blog

In addition to expanding its strategic communications team, LHS also debuted its virtual webinar series with Biotechnology Innovation Organization, including a 2021 Preview: A 360-Degree Global Market View. BOSTON & NEW YORK – January 7, 2021.

Account Executive

LaVoie Health Science Blog

Successful candidate will be a detail-oriented self-starter with 3-5 years of agency or related experience in healthcare in particular for biotechnology and pharmaceutical industries or technology. Join a health science focused integrated communications agency and be part of the agency’s second phase of growth. Strong detail oriented public relations/communications professional needed for growing life science/biopharmaceutical practice.

LaVoieHealthScience Announces Appointment of Joseph T. Schepers as Senior Vice President of Investor Relations and Financial Communications

LaVoie Health Science Blog

Further Strengthens IR Leadership Team and Supports Integrated Strategic Communications Capabilities and Continued Business Growth. link].

Donna L. LaVoie, President, CEO, and Founder of LaVoieHealthScience, Named to PharmaVOICE 100

LaVoie Health Science Blog

BOSTON AND NEW YORK – AUGUST 03, 2020. LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced that Donna L.

LHS Expert Insights: ESG Issues for Life Science Innovators

LaVoie Health Science Blog

Interviews with our senior practice managers about issues of important to life science innovators.

BTD’s Spotlight on Alliance Management: Glancing Back, Looking Forward

BTD Consulting

From pharmaceuticals & biotechnology to software & hardware to banking to oil & gas, alliances and JVs have reshaped competition. Create value. Increase value. Build or buy or borrow. Your menu. Most successful companies partake of all three.

The Secret Formula behind modern beauty brands: Interview with Organic Bioactives

Agorize

Beauty is in the eye of the beholder, but there is less debate regarding the rapid growth of the beauty and cosmetics industry. Combined with fields of deep tech, the future of beauty is not only more sustainable, environmentally friendly, but also scalable and innovative.

New Partners To Strengthen Global Community of Practice

Partnership on AI

The Transformations of the Human program at the Berggruen Institute is designed as a philosophical study and artistic exploration of the manifold ways in which artificial intelligence and biotechnology challenge our established conceptions of what it means to be human. Central to our ability to produce unique research is the diversity of our “community of practice.”

Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™

Frost & Sullivan

Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. SANTA CLARA, Calif.

Perspectives from Higher Education: Applied Sciences University Teachers on the Digitalization of the Bioeconomy

TIM Review

The term “bioeconomy” covers multiple scientific fields and interrelated perspectives highlighting biotechnology, bio-resources, and bio-ecology (Bugge et al., If we don't change, we don't grow. . Gail Sheehy. Introduction .

A Cross-Pollination of ideas about Distributed Ledger Technological Innovation through a Multidisciplinary and Multisectoral lens: Insights from the Blockchain Technology Symposium ’21

TIM Review

An example of this can be found in the Nobel Laureate, Michael Smith, of the University of British Columbia, who established a then-new interdisciplinary institute, the UBC Biotechnology Laboratory in 1986. " Cross Pollinators can create something new and better through the unexpected juxtaposition of seemingly unrelated ideas or concepts.". Tom Kelley Author of Creative Confidence, The Art of Innovation and The Ten Faces of Innovation.

A Systematic Analysis of how Practitioners Articulate Business Models across Disruptive Industries

TIM Review

Health Care : Equipment and services, pharmaceuticals, biotechnology, life science. "A powerful idea communicates some of its strength to him [or her ] who challenges it.”. Marcel Proust.

Sustainability-related Communication Patterns on the Websites of European Top R&D Spenders

TIM Review

Sustainability communications can bring your business many benefits, and help you stand out from your competitors. Amfori. A guide to effective sustainability communications . Introduction. Sustainability concerns have become a major driver of business change (Seebode et al.,